US 10875913
Methods of treatment using activatable anti-EGFR antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10875913 (Methods of treatment using activatable anti-EGFR antibodies) held by CytomX Therapeutics, Inc. expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 40
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K47/6845